Targetoid hemosiderotic hemangioma, also known as a hobnail hemangioma is a skin condition characterized by a central brown or purplish papule that is surrounded by an ecchymotic halo.It may appear similar to melanoma.It was first described by Santa Cruz and Aronberg in 1988. See also
Skin lesion
List of cutaneous conditions


== References ==
In patients with a single site of involvement, survivability tends to be very favorable. However, those with multi-organ involvement have a mortality rate of 50-66%. One systematic review calculated the disease-specific survival as 27.2 months, or 58% at one year. One group found the death rate to be 50% in patients with LCS, compared to 31% in patients who had the related condition LCH. Survivability decreases dramatically with increased disease burden and spread. LCS may be associated with other malignancies as well, such as follicular lymphoma, adenocarcinoma, and germ cell tumors. Evidence of metastatic disease or relapse from a previously treated LCS usually signifies a worsened prognosis. Treatment of these metastatic lesions or relapsed tumors may improve the patients prognosis, but there is limited evidence as to a preferred therapy. See also
Langerhans cell histiocytosis
Sarcoma

References


== External links ==